Publicaciones - Red Temática de investigación cooperativa en cáncer

PUBLICACIONES

RD12/0036/0012

Unveiling changes in the landscape of patient populations in cancer early drug development.

Hierro C, Azaro A, Argilés G, Elez E, Gómez P, Carles J, Rodon J

Oncotarget 2017. 8. 14158-14172. PMID: 27835915.

RD12/0036/0012

The expanding role of immunotherapy.

Martin-Liberal J, Ochoa de Olza M, Hierro C, Gros A, Rodon J, Tabernero J

Cancer Treat Rev 2017. 74-86. PMID: 28231560.

RD12/0036/0012

The consensus molecular subtypes of colorectal cancer.

Guinney J, Dienstmann R, Wang X, de Reyniès A, Schlicker A, Soneson C, Marisa L, Roepman P, Nyamundanda G, Angelino P, Bot BM, Morris JS, Simon IM, Gerster S, Fessler E, De Sousa E Melo F, Missiaglia E, Ramay H, Barras D, Homicsko K, Maru D, Manyam GC, Broom B, Boige V, Perez-Villamil B, Laderas T, Salazar R, Gray JW, Hanahan D, Tabernero J, Bernards R, Friend SH, Laurent-Puig P, Medema JP, Sadanandam A, Wessels L, Delorenzi M, Kopetz S, Vermeulen L, Tejpar S

Nat Med 2015. 11. 1350-6. PMID: 26457759.

RD12/0036/0012

Subgroup analysis in RAISE: a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression.

Obermannová R, Van Cutsem E, Yoshino T, Bodoky G, Prausová J, Garcia-Carbonero R, Ciuleanu T, Garcia Alfonso P, Portnoy D, Cohn A, Yamazaki K, Clingan P, Lonardi S, Kim TW, Yang L, Nasroulah F, Tabernero J

Ann Oncol 2016. 11. 2082-2090. PMID: 27573561.

RD12/0036/0012

Single-cell transcriptome conservation in cryopreserved cells and tissues.

Guillaumet-Adkins A, Rodríguez-Esteban G, Mereu E, Mendez-Lago M, Jaitin DA, Villanueva A, Vidal A, Martinez-Marti A, Felip E, Vivancos A, Keren-Shaul H, Heath S, Gut M, Amit I, Gut I, Heyn H

Genome Biol 2017. 1. 45. PMID: 28249587.

RD12/0036/0012

Sequence variation in mature microRNA-608 and benefit from neo-adjuvant treatment in locally advanced rectal cancer patients.

Sclafani F, Chau I, Cunningham D, Lampis A, Hahne JC, Ghidini M, Lote H, Zito D, Tabernero J, Glimelius B, Cervantes A, Begum R, De Castro DG, Wilson SH, Peckitt C, Eltahir Z, Wotherspoon A, Tait D, Brown G, Oates J, Braconi C, Valeri N

Carcinogenesis 2016. 9. 852-7. PMID: 27381831.

RD12/0036/0012

SEOM Clinical Guideline for the treatment of pancreatic cancer (2016).

Vera R, Dotor E, Feliu J, González E, Laquente B, Macarulla T, Martínez E, Maurel J, Salgado M, Manzano JL

Clin Transl Oncol 2016. 12. 1172-1178. PMID: 27896637.

RD12/0036/0012

Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer.

Chiorean EG, Von Hoff DD, Tabernero J, El-Maraghi R, Wee Ma W, Reni M, Harris M, Whorf R, Liu H, Shiansong Li J, Manax V, Romano A, Lu B, Goldstein D

Br J Cancer 2016. 9. e13. PMID: 27657342.

RD12/0036/0012

Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer.

Chiorean EG, Von Hoff DD, Tabernero J, El-Maraghi R, Ma WW, Reni M, Harris M, Whorf R, Liu H, Li JS, Manax V, Romano A, Lu B, Goldstein D

Br J Cancer 2016. 2. 188-94. PMID: 27351217.

RD12/0036/0012

Resistance to Targeted Therapies in Renal Cancer: The Importance of Changing the Mechanism of Action.

Duran I, Lambea J, Maroto P, González-Larriba JL, Flores L, Granados-Principal S, Graupera M, Sáez B, Vivancos A, Casanovas O

Target Oncol 2017. 1. 19-35. PMID: 27844272.

RD12/0036/0012

Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal Cancer.

García-Carbonero R, van Cutsem E, Rivera F, Jassem J, Gore I Jr, Tebbutt N, Braiteh F, Argiles G, Wainberg ZA, Funke R, Anderson M, McCall B, Stroh M, Wakshull E, Hegde P, Ye W, Chen D, Chang I, Rhee I, Hurwitz H

Oncologist 2017. 4. 375-e30. PMID: 28275117.

RD12/0036/0012

Quality of life during first-line FOLFOX4±panitumumab in RAS wild-type metastatic colorectal carcinoma: results from a randomised controlled trial.

Siena S, Tabernero J, Bodoky G, Cunningham D, Rivera F, Ruff P, Canon JL, Koukakis R, Demonty G, Hechmati G, Douillard JY

ESMO Open 2016. 2. e000041. PMID: 27843597.

RD12/0036/0012

Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer.

Taieb J, Le Malicot K, Shi Q, Penault Lorca F, Bouché O, Tabernero J, Mini E, Goldberg RM, Folprecht G, Luc Van Laethem J, Sargent DJ, Alberts SR, Emile JF, Laurent Puig P, Sinicrope FA

J Natl Cancer Inst 2017. 5. PMID: 28040692.

RD12/0036/0012

Prognostic Effect of BRAF and KRAS Mutations in Patients With Stage III Colon Cancer Treated With Leucovorin, Fluorouracil, and Oxaliplatin With or Without Cetuximab: A Post Hoc Analysis of the PETACC-8 Trial.

Taieb J, Zaanan A, Le Malicot K, Julié C, Blons H, Mineur L, Bennouna J, Tabernero J, Mini E, Folprecht G, Van Laethem JL, Lepage C, Emile JF, Laurent-Puig P

JAMA Oncol 2016. 1-11. PMID: 26768652.

RD12/0036/0012

Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors.

Tabernero J, Bahleda R, Dienstmann R, Infante JR, Mita A, Italiano A, Calvo E, Moreno V, Adamo B, Gazzah A, Zhong B, Platero SJ, Smit JW, Stuyckens K, Chatterjee-Kishore M, Rodon J, Peddareddigari V, Luo FR, Soria JC

J Clin Oncol 2015. 30. 3401-8. PMID: 26324363.

RD12/0036/0012

Pharmacokinetic/Pharmacodynamic Modeling for Drug Development in Oncology.

Garralda E, Dienstmann R, Tabernero J

Am Soc Clin Oncol Educ Book 2017. 210-215. PMID: 28561730.

RD12/0036/0012

PAN-EX: a pooled analysis of two trials of neoadjuvant chemotherapy followed by chemoradiotherapy in MRI-defined, locally advanced rectal cancer.

Sclafani F, Brown G, Cunningham D, Wotherspoon A, Tait D, Peckitt C, Evans J, Yu S, Sena Teixeira Mendes L, Tabernero J, Glimelius B, Cervantes A, Thomas J, Begum R, Oates J, Chau I

Ann Oncol 2016. 8. 1557-65. PMID: 27217542.

RD12/0036/0012

nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: a subgroup analysis of the Western European cohort of the MPACT trial.

Tabernero J, Kunzmann V, Scheithauer W, Reni M, Shiansong Li J, Ferrara S, Djazouli K

Onco Targets Ther 2017. 591-596. PMID: 28203092.

RD12/0036/0012

Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.

Oddo D, Sennott EM, Barault L, Valtorta E, Arena S, Cassingena A, Filiciotto G, Marzolla G, Elez E, van Geel RM, Bartolini A, Crisafulli G, Boscaro V, Godfrey JT, Buscarino M, Cancelliere C, Linnebacher M, Corti G, Truini M, Siravegna G, Grasselli J, Gallicchio M, Bernards R, Schellens JH, Tabernero J, Engelman JA, Sartore-Bianchi A, Bardelli A, Siena S, Corcoran RB, Di Nicolantonio F

Cancer Res 2016. 15. 4504-15. PMID: 27312529.

RD12/0036/0012

Letter to the editor regarding the paper by A. Lozano-Blázquez et al. Differences in cancer drug assessment between Spain and the United Kingdom.

Prat A, Gilabert A, Puig-Peiro R, Feliu A, Riba M, Mangues MA, Tabernero J

Eur J Cancer 2016. 55-56. PMID: 27599024.

RD12/0036/0012

Integrated genomic analysis of colorectal cancer progression reveals activation of EGFR through demethylation of the EREG promoter.

Qu X, Sandmann T, Frierson H Jr, Fu L, Fuentes E, Walter K, Okrah K, Rumpel C, Moskaluk C, Lu S, Wang Y, Bourgon R, Penuel E, Pirzkall A, Amler L, Lackner MR, Tabernero J, Hampton GM, Kabbarah O

Oncogene 2016. 50. 6403-6415. PMID: 27270421.

RD12/0036/0012

Immunotherapy for Gastric Cancer: A Focus on Immune Checkpoints.

Alsina M, Moehler M, Hierro C, Guardeño R, Tabernero J

Target Oncol 2016. 4. 469-77. PMID: 26880697.

RD12/0036/0012

First-Line Treatment of Metastatic Colorectal Cancer: Interpreting FIRE-3, PEAK, and CALGB/SWOG 80405.

Elez E, Argilés G, Tabernero J

Curr Treat Options Oncol 2015. 11. 52. PMID: 26374340.

RD12/0036/0012

ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016.

Dittrich C, Kosty M, Jezdic S, Pyle D, Berardi R, Bergh J, El-Saghir N, Lotz JP, Österlund P, Pavlidis N, Purkalne G, Awada A, Banerjee S, Bhatia S, Bogaerts J, Buckner J, Cardoso F, Casali P, Chu E, Close JL, Coiffier B, Connolly R, Coupland S, De Petris L, De Santis M, de Vries EG, Dizon DS, Duff J, Duska LR, Eniu A, Ernstoff M, Felip E, Fey MF, Gilbert J, Girard N, Glaudemans AW, Gopalan PK, Grothey A, Hahn SM, Hanna D, Herold C, Herrstedt J, Homicsko K, Jones DV Jr, Jost L, Keilholz U, Khan S, Kiss A, Köhne CH, Kunstfeld R, Lenz HJ, Lichtman S, Licitra L, Lion T, Litière S, Liu L, Loehrer PJ, Markham MJ, Markman B, Mayerhoefer M, Meran JG, Michielin O, Moser EC, Mountzios G, Moynihan T, Nielsen T, Ohe Y, Öberg K, Palumbo A, Peccatori FA, Pfeilstöcker M, Raut C, Remick SC, Robson M, Rutkowski P, Salgado R, Schapira L, Schernhammer E, Schlumberger M, Schmoll HJ, Schnipper L, Sessa C, Shapiro CL, Steele J, Sternberg CN, Stiefel F, Strasser F, Stupp R, Sullivan R, Tabernero J, Travado L, Verheij M, Voest E, Vokes E, Von Roenn J, Weber JS, Wildiers H, Yarden Y

ESMO Open 2016. 5. e000097. PMID: 27843641.

RD12/0036/0012

ESMO - Magnitude of Clinical Benefit Scale V.1.0 questions and answers.

Cherny NI, Sullivan R, Dafni U, Kerst JM, Sobrero A, Zielinski C, Piccart MJ, Bogaerts J, Tabernero J, Latino NJ, de Vries EG

ESMO Open 2016. 5. e000100. PMID: 27900206.

RD12/0036/0012

Emerging tyrosine kinase inhibitors for the treatment of metastatic colorectal cancer.

Matos I, Elez E, Capdevila J, Tabernero J

Expert Opin Emerg Drugs 2016. 3. 267-82. PMID: 27578253.

RD12/0036/0012

Efficacy of trifluridine and tipiracil (TAS-102) versus placebo, with supportive care, in a randomized, controlled trial of patients with metastatic colorectal cancer from Spain: results of a subgroup analysis of the phase 3 RECOURSE trial.

Longo-Muñoz F, Argiles G, Tabernero J, Cervantes A, Gravalos C, Pericay C, Gil-Calle S, Mizuguchi H, Carrato-Mena A, Limón ML, Garcia-Carbonero R

Clin Transl Oncol 2017. 2. 227-235. PMID: 27443414.

RD12/0036/0012

Determination of somatic oncogenic mutations linked to target-based therapies using MassARRAY technology.

Ibarrola-Villava M, Fleitas T, Llorca-Cardeñosa MJ, Mongort C, Alonso E, Navarro S, Burgues O, Vivancos A, Cejalvo JM, Perez-Fidalgo JA, Roselló S, Ribas G, Cervantes A

Oncotarget 2016. 16. 22543-55. PMID: 26968814.

RD12/0036/0012

Dalotuzumab in chemorefractory KRAS exon 2 mutant colorectal cancer: Results from a randomised phase II/III trial.

Sclafani F, Kim TY, Cunningham D, Kim TW, Tabernero J, Schmoll HJ, Roh JK, Kim SY, Park YS, Guren TK, Hawkes E, Clarke SJ, Ferry D, Frodin JE, Ayers M, Nebozhyn M, Peckitt C, Loboda A, Watkins DJ

Int J Cancer 2017. 2. 431-439. PMID: 27681944.

RD12/0036/0012

Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer.

Dienstmann R, Vermeulen L, Guinney J, Kopetz S, Tejpar S, Tabernero J

Nat Rev Cancer 2017. 4. 268. PMID: 28332502.

RD12/0036/0012

Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer.

Dienstmann R, Vermeulen L, Guinney J, Kopetz S, Tejpar S, Tabernero J

Nat Rev Cancer 2017. 2. 79-92. PMID: 28050011.

RD12/0036/0012

Challenging chemoresistant metastatic colorectal cancer: therapeutic strategies from the clinic and from the laboratory.

Sartore-Bianchi A, Loupakis F, Argilés G, Prager GW

Ann Oncol 2016. 8. 1456-66. PMID: 27154421.

RD12/0036/0012

Career opportunities and benefits for young oncologists in the European Society for Medical Oncology (ESMO).

Morgan G, Lambertini M, Kourie HR, Amaral T, Argiles G, Banerjee S, Cardone C, Corral J, De Mattos-Arruda L, Öztürk A, Petrova M, Poulsen L, Strijbos M, Tyulyandina A, Vidra R, Califano R, de Azambuja E, Garrido Lopez P, Guarneri V, Reck M, Moiseyenko V, Martinelli E, Douillard JY, Stahel R, Voest E, Arnold D, Cardoso F, Casali P, Cervantes A, Eggermont AM, Eniu A, Jassem J, Pentheroudakis G, Peters S, McGregor K, Rauh S, Zielinski CC, Ciardiello F, Tabernero J, Preusser M

ESMO Open 2016. 6. e000107. PMID: 28255451.

RD12/0036/0012

Brexit: a European perspective.

Tabernero J, Ciardiello F

Lancet Oncol 2016. 5. 558-9. PMID: 27301028.

RD12/0036/0012

Biomarker analyses in REGARD gastric/GEJ carcinoma patients treated with VEGFR2-targeted antibody ramucirumab.

Fuchs CS, Tabernero J, Tomá?ek J, Chau I, Melichar B, Safran H, Tehfe MA, Filip D, Topuzov E, Schlittler L, Udrea AA, Campbell W, Brincat S, Emig M, Melemed SA, Hozak RR, Ferry D, Caldwell CW, Ajani JA

Br J Cancer 2016. 8. 974-982. PMID: 27623234.

RD12/0036/0012

Baseline carcinoembryonic antigen as a predictive factor of ramucirumab efficacy in RAISE, a second-line metastatic colorectal carcinoma phase III trial.

Yoshino T, Obermannová R, Bodoky G, Garcia-Carbonero R, Ciuleanu T, Portnoy DC, Kim TW, Hsu Y, Ferry D, Nasroulah F, Tabernero J

Eur J Cancer 2017. 61-69. PMID: 28412590.

RD12/0036/0012

Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study.

Caplin ME, Pavel M, ?wik?a JB, Phan AT, Raderer M, Sedlá?ková E, Cadiot G, Wolin EM, Capdevila J, Wall L, Rindi G, Langley A, Martinez S, Gomez-Panzani E, Ruszniewski P, CLARINET Investigators.

Endocr Relat Cancer 2016. 3. 191-9. PMID: 26743120.

RD12/0036/0012

Antiangiogenic therapies in gastric cancer: trusting the pathway.

Alsina M, Hierro C, Tabernero J

Ann Oncol 2016. 12. 2141-2143. PMID: 27742655.

RD12/0036/0012

Adjuvant FOLFOX +/- cetuximab in full RAS and BRAF wildtype stage III colon cancer patients.

Taieb J, Balogoun R, Le Malicot K, Tabernero J, Mini E, Folprecht G, Van Laethem JL, Emile JF, Mulot C, Fratté S, Levaché CB, Saban-Roche L, Thaler J, Petersen LN, Bridgewater J, Perkins G, Lepage C, Van Cutsem E, Zaanan A, Laurent-Puig P, for PETACC8 Investigators.

Ann Oncol 2017. 4. 824-830. PMID: 28031175.

RD12/0036/0012

A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors.

Saura C, Roda D, Roselló S, Oliveira M, Macarulla T, Pérez-Fidalgo JA, Morales-Barrera R, Sanchis-García JM, Musib L, Budha N, Zhu J, Nannini M, Chan WY, Sanabria Bohórquez SM, Meng RD, Lin K, Yan Y, Patel P, Baselga J, Tabernero J, Cervantes A

Cancer Discov 2017. 1. 102-113. PMID: 27872130.

RD12/0036/0043

MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients.

De Mattos-Arruda L, Bottai G, Nuciforo PG, Di Tommaso L, Giovannetti E, Peg V, Losurdo A, Pérez-Garcia J, Masci G, Corsi F, Cortés J, Seoane J, Calin GA, Santarpia L

Oncotarget 2015. 35. 37269-80. PMID: 26452030.

Grupos colaboradores: RD12/0036/0057 , RD12/0036/0043

RD12/0036/0030

Selenium Increases Thyroid-Stimulating Hormone-Induced Sodium/Iodide Symporter Expression Through Thioredoxin/Apurinic/Apyrimidinic Endonuclease 1-Dependent Regulation of Paired Box 8 Binding Activity.

Leoni SG, Sastre-Perona A, De la Vieja A, Santisteban P

Antioxid Redox Signal 2016. 15. 855-66. PMID: 26650895.

RD12/0036/0030

?-catenin signaling is required for RAS-driven thyroid cancer through PI3K activation.

Sastre-Perona A, Riesco-Eizaguirre G, Zaballos MA, Santisteban P

Oncotarget 2016. 31. 49435-49449. PMID: 27384483.

RD12/0036/0030

ENDOCRINE TUMOURS: Advances in the molecular pathogenesis of thyroid cancer: lessons from the cancer genome.

Riesco-Eizaguirre G, Santisteban P

Eur J Endocrinol 2016. 5. R203-17. PMID: 27666535.

RD12/0036/0030

The Prognostic Value of Tumor Multifocality in Clinical Outcomes of Papillary Thyroid Cancer.

Wang F, Yu X, Shen X, Zhu G, Huang Y, Liu R, Viola D, Elisei R, Puxeddu E, Fugazzola L, Colombo C, Jarzab B, Czarniecka A, Lam AK, Mian C, Vianello F, Yip L, Riesco-Eizaguirre G, Santisteban P, O'Neill CJ, Sywak MS, Clifton-Bligh R, Bendlova B, Sýkorová V, Wang Y, Liu S, Zhao J, Zhao S, Xing M

J Clin Endocrinol Metab 2017. PMID: 28582521.

RD12/0036/0030

Differential Clinicopathological Risk and Prognosis of Major Papillary Thyroid Cancer Variants.

Shi X, Liu R, Basolo F, Giannini R, Shen X, Teng D, Guan H, Shan Z, Teng W, Musholt TJ, Al-Kuraya K, Fugazzola L, Colombo C, Kebebew E, Jarzab B, Czarniecka A, Bendlova B, Sykorova V, Sobrinho-Simões M, Soares P, Shong YK, Kim TY, Cheng S, Asa SL, Viola D, Elisei R, Yip L, Mian C, Vianello F, Wang Y, Zhao S, Oler G, Cerutti JM, Puxeddu E, Qu S, Wei Q, Xu H, O'Neill CJ, Sywak MS, Clifton-Bligh R, Lam AK, Riesco-Eizaguirre G, Santisteban P, Yu H, Tallini G, Holt EH, Vasko V, Xing M

J Clin Endocrinol Metab 2016. 1. 264-74. PMID: 26529630.

RD12/0036/0030

Pax8 controls thyroid follicular polarity through cadherin-16.

Koumarianou P, Goméz-López G, Santisteban P

J Cell Sci 2017. 1. 219-231. PMID: 27780871.

RD12/0036/0038

The addition of celecoxib improves the antitumor effect of cetuximab in colorectal cancer: role of EGFR-RAS-FOXM1-?- catenin signaling axis.

Valverde A, Peñarando J, Cañas A, López-Sánchez LM, Conde F, Guil-Luna S, Hernández V, Villar C, Morales-Estévez C, de la Haba-Rodríguez J, Aranda E, Rodríguez-Ariza A

Oncotarget 2017. 13. 21754-21769. PMID: 28423516.

RD12/0036/0038

Gemcitabine-erlotinib versus gemcitabine-erlotinib-capecitabine in the first-line treatment of patients with metastatic pancreatic cancer: Efficacy and safety results of a phase IIb randomised study from the Spanish TTD Collaborative Group.

Irigoyen A, Gallego J, Guillén Ponce C, Vera R, Iranzo V, Ales I, Arévalo S, Pisa A, Martín M, Salud A, Falcó E, Sáenz A, Manzano Mozo JL, Pulido G, Martínez Galán J, Pazo-Cid R, Rivera F, García García T, Serra O, Fernández Parra EM, Hurtado A, Gómez Reina MJ, López Gomez LJ, Martínez Ortega E, Benavides M, Aranda E, Spanish Cooperative Group of Treatment of Digestive Tumors (TTD).

Eur J Cancer 2017. 73-82. PMID: 28222309.

RD12/0036/0038

Identification of gene expression profiling associated with erlotinib-related skin toxicity in pancreatic adenocarcinoma patients.

Caba O, Irigoyen A, Jimenez-Luna C, Benavides M, Ortuño FM, Gallego J, Rojas I, Guillen-Ponce C, Torres C, Aranda E, Prados J

Toxicol Appl Pharmacol 2016. 113-116. PMID: 27720938.

Ver todas »

« volver